Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia

American Journal of Psychiatry

Volumn 171, Issue 10, 2014, Pages 1091-1098

  Telch, Michael J ^a   Bruchey, Aleksandra K ^a   Rosenfield, David ^a   Cobb, Adam R ^a   Smits, Jasper ^a   Pahl, Sandra ^a   Gonzalez Lima, F ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLENE BLUE; PLACEBO; NOOTROPIC AGENT;

ABNORMAL FECES; ABNORMAL URINE COMPOSITION; ADULT; ARTICLE; BLADDER IRRITATION; CLAUSTROPHOBIA; CLINICAL ARTICLE; CLINICAL PRACTICE; COGNITIVE THERAPY; CONTEXTUAL MEMORY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; EXTINCTION TRAINING; FEAR; FEAR EXTINCTION; FECAL DISCOLORATION; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; IN VIVO STUDY; INDIGESTION; LOW DRUG DOSE; MALE; MEMORY; MEMORY CONSOLIDATION; MICTURITION DISORDER; RANDOMIZED CONTROLLED TRIAL; RECALL; REINFORCEMENT; SLEEP DISORDER; TREATMENT OUTCOME; URINE DISCOLORATION; VOMITING; ADOLESCENT; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MULTIMODALITY CANCER THERAPY; PHOBIC DISORDERS; PSYCHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; EXTINCTION, PSYCHOLOGICAL; FEAR; FEMALE; HUMANS; MALE; MEMORY; METHYLENE BLUE; NOOTROPIC AGENTS; PHOBIC DISORDERS; YOUNG ADULT;

EID: 84907552207     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2014.13101407     Document Type: Article

References (56)

1. Neudeck P, Wittchen H-U: Exposure Therapy: Rethinking the Model-Refining the Method. New York, Springer, 2012
2. Telch MJ, Cobb AR, Lancaster CL: Exposure therapy for anxiety disorders: procedural variations, clinical efficacy, and change mechanisms, in International Handbook of Anxiety Disorders. Edited by Emmelkamp PM, Ehring T. Ames, Iowa, Wiley-Blackwell, 2013
3. McNally RJ: Mechanisms of exposure therapy: how neuroscience can improve psychological treatments for anxiety disorders. Clin Psychol Rev 2007; 27:750-759
4. Craske MG, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker A: Optimizing inhibitory learning during exposure therapy. Behav Res Ther 2008; 46:5-27
5. Davis M, Ressler K, Rothbaum BO, Richardson R: Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 2006; 60:369-375
6. Hofmann SG, Sawyer AT, Asnaani A: D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update. Curr Pharm Des 2012; 18:5659-5662
7. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M: Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61:1136-1144
8. Hofmann SG, Meuret AE, Smits JAJ, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW: Augmentation of exposure therapy with D -cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63:298-304
9. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR: A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63:544-549
10. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH: Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 2010; 67:365-370
11. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB: D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62:835-838
12. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL: Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008; 165:335-341, quiz 409
13. Hofmann SG, Smits JAJ, Rosenfield D, Simon N, Otto MW, Meuret AE, Marques L, Fang A, Tart C, Pollack MH: D-cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry 2013; 170:751-758
14. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, Geffken GR, Goodman WK: D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007; 22:230-237
15. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R: A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res 2007; 41:466-471
16. Tart CD, Handelsman PR, Deboer LB, Rosenfield D, Pollack MH, Hofmann SG, Powers MB, Otto MW, Smits JAJ: Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res 2013; 47:168-174
17. Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, Hofmann SG: A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 2012; 46:1184-1190
18. Wainwright M, Crossley KB: Methylene blue: a therapeutic dye for all seasons? J Chemother 2002; 14:431-443
19. Rojas JC, Bruchey AK, Gonzalez-Lima F: Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 2012; 96:32-45
20. Lin A-L, Poteet E, Du F, Gourav RC, Liu R, Wen Y, Bresnen A, Huang S, Fox PT, Yang S-H, Duong TQ: Methylene blue as a cerebral metabolic and hemodynamic enhancer. PLoS ONE 2012;7:e46585
21. Huang S, Du F, Shih Y-YI, Shen Q, Gonzalez-Lima F, Duong TQ: Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia. Neuroimage 2013; 72:237-242
22. Gonzalez-Lima F, Bruchey AK: Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem 2004; 11:633-640
23. Martinez JL Jr, Jensen RA, Vasquez BJ, McGuinness T, McGaugh JL: Methylene blue alters retention of inhibitory avoidance responses. Physiol Psychol 1978; 6:387-390
24. Riha PD, Bruchey AK, Echevarria DJ, Gonzalez-Lima F: Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption. Eur J Pharmacol 2005; 511:151-158
25. Medina DX, Caccamo A, Oddo S: Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 2011; 21:140-149
26. O'Leary JC 3rd, Li Q, Marinec P, Blair LJ, Congdon EE, Johnson AG, Jinwal UK, Koren J 3rd, Jones JR, Kraft C, Peters M, Abisambra JF, Duff KE, Weeber EJ, Gestwicki JE, Dickey CA: Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 2010; 5:45
27. Callaway NL, Riha PD, Bruchey AK, Munshi Z, Gonzalez-Lima F: Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav 2004; 77:175-181
28. Wrubel KM, Riha PD, Maldonado MA, McCollum D, Gonzalez-Lima F: The brain metabolic enhancer methylene blue improves discrimination learning in rats. Pharmacol Biochem Behav 2007; 86:712-717
29. Wrubel KM, Barrett D, Shumake J, Johnson SE, Gonzalez-Lima F: Methylene blue facilitates the extinction of fear in an animal model of susceptibility to learned helplessness. Neurobiol Learn Mem 2007; 87:209-217
30. Barrett D, Shumake J, Jones D, Gonzalez-Lima F: Metabolic mapping of mouse brain activity after extinction of a conditioned emotional response. J Neurosci 2003; 23:5740-5749
31. Quirk GJ, Garcia R, González-Lima F: Prefrontal mechanisms in extinction of conditioned fear. Biol Psychiatry 2006; 60:337-343
32. Milad MR, Quirk GJ: Fear extinction as a model for translational neuroscience: ten years of progress. Annu Rev Psychol 2012; 63:129-151
33. Smits JAJ, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ, Pollack MH, Tart CD: D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 2013; 73:1054-1058
34. Smits JAJ, Rosenfield D, Davis ML, Julian K, Handelsman PR, Otto MW, Tuerk P, Shiekh M, Rosenfield B, Hofmann SG, Powers MB: Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial. Biol Psychiatry 75:840-846 2014
35. Rachman PDS, Taylor PDS: Analyses of claustrophobia. J Anxiety Disord 1993; 7:281-291
36. Valentiner DP, Telch MJ, Ilai D, Hehmsoth MM: Claustrophobic fear behavior: a test of the expectancy model of fear. Behav Res Ther 1993; 31:395-402
37. First MB, Spitzer RL, Gibbon M, Williams JB: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). New York, New York State Psychiatric Institute, Biometrics Research, 1994
38. Powers MB, Smits JAJ, Whitley D, Bystritsky A, Telch MJ: The effect of attributional processes concerning medication taking on return of fear. J Consult Clin Psychol 2008; 76:478-490
39. Powers MB, Smits JAJ, Telch MJ: Disentangling the effects of safety-behavior utilization and safety-behavior availability during exposure-based treatment: a placebo-controlled trial. J Consult Clin Psychol 2004; 72:448-454
40. Sloan T, Telch MJ: The effects of safety-seeking behavior and guided threat reappraisal on fear reduction during exposure: an experimental investigation. Behav Res Ther 2002; 40:235-251
41. Telch MJ, Valentiner DP, Ilai D, Petruzzi D, Hehmsoth M: The facilitative effects of heart-rate feedback in the emotional processing of claustrophobic fear. Behav Res Ther 2000; 38: 373-387
42. Kamphuis JH, Telch MJ: Effects of distraction and guided threat reappraisal on fear reduction during exposure-based treatments for specific fears. Behav Res Ther 2000; 38:1163-1181
43. Peter C, Hongwan D, Küpfer A, Lauterburg BH: Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000; 56:247-250
44. Corrêa MS, Balardin JB, Caldieraro MAK, Fleck MP, Argimon I, Luz C, Bromberg E: Contextual recognition memory deficits in major depression are suppressed by cognitive support at encoding. Biol Psychol 2012; 89:293-299
45. Vicari S, Finzi A, Menghini D, Marotta L, Baldi S, Petrosini L: Do children with developmental dyslexia have an implicit learning deficit? J Neurol Neurosurg Psychiatry 2005; 76:1392-1397
46. Vicari S, Bellucci S, Carlesimo GA: Visual and spatial long-term memory: differential pattern of impairments in Williams and Down syndromes. Dev Med Child Neurol 2005; 47:305-311
47. Kraemer HC, Kiernan M, Essex M, Kupfer DJ: How and why criteria defining moderators and mediators differ between the Baron and Kenny and MacArthur approaches. Health Psychol 2008; 27(suppl):S101-S108
48. Steiner PM, Cook TD, Shadish WR, Clark MH: The importance of covariate selection in controlling for selection bias in observational studies. Psychol Methods 2010; 15:250-267
49. Aiken LS, West SG: Multiple Regression: Testing and Interpreting Interactions. Thousand Oaks, Calif, Sage Publications, 1991
50. Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal B, de Quervain DJ: Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA 2006; 103:5585-5590
51. Maren S, Phan KL, Liberzon I: The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat Rev Neurosci 2013; 14:417-428
52. Orsini CA, Kim JH, Knapska E, Maren S: Hippocampal and prefrontal projections to the basal amygdala mediate contextual regulation of fear after extinction. J Neurosci 2011; 31:17269-17277
53. Krystal JH: Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: new opportunities for synergy with psychotherapy. Biol Psychiatry 2007; 62:833-834
54. Eich E, Context, memory, and integrated item/context imagery. J Exp Psych Learn 1985; 11:764
55. Hintzman DL: Judgments of frequency and recognition memory in a multiple-trace memory model. Psychol Rev 1988; 95:528
56. Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ: Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev 2008; 28:1021-1037